Apricus Biosciences Inc (APRI)

1.45
0.05 3.30
NASDAQ : Health Care
Prev Close 1.50
Open 1.52
Day Low/High 1.42 / 1.54
52 Wk Low/High 0.32 / 1.99
Volume 266.56K
Avg Volume 419.80K
Exchange NASDAQ
Shares Outstanding 12.78M
Market Cap 17.39M
EPS -1.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Apricus Biosciences Announces The Initiation Of Vitaros Drug-Device Human Factors Study

Vitaros U.S. NDA Re-Submission on Track for Third Quarter 2017

Apricus Biosciences Announces Approval Of Vitaros® For The Treatment Of Erectile Dysfunction In Mexico

Apricus Biosciences Announces Approval Of Vitaros® For The Treatment Of Erectile Dysfunction In Mexico

Ferring Plans to Launch in Mexico and Argentina During the Second Quarter 2017

Apricus Biosciences Announces The Launch Of Vitaros® For The Treatment Of Erectile Dysfunction In Lebanon By Elis Pharmaceuticals

Apricus Biosciences Announces The Launch Of Vitaros® For The Treatment Of Erectile Dysfunction In Lebanon By Elis Pharmaceuticals

Continued Commercial Expansion in the Middle East Expected to Increase Royalty Revenue for Apricus

Apricus Biosciences Receives Nasdaq Compliance Notice

Apricus Biosciences Receives Nasdaq Compliance Notice

Company Intends to Request Hearing

Apricus Biosciences Provides Update On Vitaros NDA Following Receipt Of FDA Feedback

Apricus Biosciences Provides Update On Vitaros NDA Following Receipt Of FDA Feedback

Apricus Re-Affirms Plans to Re-Submit Vitaros U.S. NDA

Apricus Biosciences Announces Approval Of Vitaros® For The Treatment Of Erectile Dysfunction In Greece

Apricus Biosciences Announces Approval Of Vitaros® For The Treatment Of Erectile Dysfunction In Greece

Recordati Targeting Launch in Greece in First Half of 2017

Apricus Biosciences Announces The Launch Of Vitaros® In The Czech Republic And Slovakia By Recordati

Apricus Biosciences Announces The Launch Of Vitaros® In The Czech Republic And Slovakia By Recordati

Continued Commercial Expansion in Europe Expected to Increase Royalty Revenue for Apricus

Apricus Biosciences Announces Completion Of Transfer Of The Marketing Authorizations For Vitaros® In Finland And Denmark To Ferring Pharmaceuticals

Apricus Biosciences Announces Completion Of Transfer Of The Marketing Authorizations For Vitaros® In Finland And Denmark To Ferring Pharmaceuticals

Ferring Demonstrates Continued Progress Towards Building the Vitaros Brand in Europe

Apricus Biosciences Announces Approval Of Vitaros® For The Treatment Of Erectile Dysfunction In Argentina

Apricus Biosciences Announces Approval Of Vitaros® For The Treatment Of Erectile Dysfunction In Argentina

First Vitaros Approval in Latin America, Registrations Also Filed in Mexico and Colombia

Apricus Biosciences Announces The Launch Of Its Novel Topical Treatment For Erectile Dysfunction In Portugal, Ireland And Poland By Recordati

Apricus Biosciences Announces The Launch Of Its Novel Topical Treatment For Erectile Dysfunction In Portugal, Ireland And Poland By Recordati

To be Commercialized in Portugal and Ireland as Vitaros® and in Poland as Vytaros®